A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

NCT03809767 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Lymphoma

Interventions

DRUG: CS1003 monoclonal antibody

Sponsor

CStone Pharmaceuticals